G1 Therapeutics (G1 Therapeutics) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is G1 Therapeutics Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

G1 Therapeutics's Capital Expenditure for the three months ended in Dec. 2023 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was $-12.79 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.

G1 Therapeutics Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for G1 Therapeutics's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G1 Therapeutics Capex-to-Operating-Cash-Flow Chart

G1 Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Operating-Cash-Flow

Get a 7-Day Free Trial

G1 Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Capex-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of G1 Therapeutics's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, G1 Therapeutics's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

G1 Therapeutics's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, G1 Therapeutics's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where G1 Therapeutics's Capex-to-Operating-Cash-Flow falls into.

G1 Therapeutics Capex-to-Operating-Cash-Flow Calculation

G1 Therapeutics's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow	=	- Capital Expenditure	/	Cash Flow from Operations
	=	- (0)	/	-38.337
	=	N/A

G1 Therapeutics's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow	=	- Capital Expenditure	/	Cash Flow from Operations
	=	- (0)	/	-12.792
	=	N/A

G1 Therapeutics (NAS:GTHX) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.

G1 Therapeutics Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of G1 Therapeutics's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

G1 Therapeutics (G1 Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » G1 Therapeutics Inc (NAS:GTHX) » Definitions » Capex-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

G1H:Germany

Address

700 Park Offices Drive, Suite 200, Research Triangle Park, NC, USA, 27709

Website

https://www.g1therapeutics.com

G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine - and enhance - the anti-tumor activity of current therapies.

Executives

John V. Umstead	officer: Chief Financial Officer	C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Rajesh Malik	officer: Chief Medical Officer	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Mark Avagliano	officer: Chief Business Officer	79 T.W. ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Terry L Murdock	officer: Chief Operating Officer
Bailey John E. (jack) Jr.	director, officer: President and CEO	C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Andrew Perry	officer: Chief Commercial Officer	C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Mark A. Velleca	director, officer: President and CEO	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Monica R. Thomas	officer: General Counsel	700 PARK OFFICES, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Jennifer K. Moses	officer: CFO	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
James S. Hanson	officer: General Counsel	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Norman Sharpless	director	700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 22709
Jacks Lee	director	700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Seth Rudnick	director	7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS, MISSISSAUGA A6 L5N 0E4
Alicia Secor	director	33 HAYDEN AVE., LEXINGTON MA 02421
Soma Gupta	officer: Chief Commercial Officer	C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709